Less pronounced enhancement of thrombin-dependent inactivation of plasminogen activator inhibitor type 1 by low molecular weight heparin compared with unfractionated heparin

Summary

Plasminogen activator inhibitor type 1 (PAI-1), the primary inhibitor of plasminogen activators, also forms high molecular weight complexes with either thrombin or factor Xa (FXa) in the presence of heparin, resulting in the loss of mutual activities of enzyme and inhibitor.We have proposed that the inactivation of PAI-1 by these activated coagulation factors is one of the mechanisms responsible for coagulation-associated enhancement of fibrinolysis. In the present study, we compared the effects of low molecular weight (LMW)- and unfractionated-heparin on the interaction between PAI-1 and either thrombin or FXa. Both types of heparin enhanced the inhibition of thrombin activity by PAI-1 with a bell-shaped pattern, though the magnitude of the enhancement was significantly weaker with LMW-heparin. In FXa inhibition by PAI-1, only unfractionated-heparin enhanced the inhibition. In the presence of vitronectin (Vn), the inhibition of thrombin and FXa by PAI-1 was further promoted by both types of heparin but toa significantly lesser extent with LMW-heparin.We then analyzed the possible enhancing effect of heparin on tissue plasminogen activator (tPA)-induced fibrinolysis. As a consequence of thrombin-dependent inactivation of PAI-1, tPA-induced fibrin clot lysis time in the presence of PAI-1 was shortened by unfractionated-heparin as well as by LMW-heparin with lesser extent, which was further enhanced by Vn. Less pronounced enhancement of complex formation between thrombin and PAI-1 by LMW-heparin appeared to be directly related to the weaker potential of LMW-heparin in enhancing fibrinolysis and accelerating hemorrhagic tendency via neutralization of PAI-1 activity.

Keywords

Plasminogen activator inhibitor type 1 - low molecular weight heparin - unfractionated heparin - thrombin - vitronectin

• References

• 1 Loskutoff DJ. et al. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb 1989; 09: 87-115.
• 2 Urano T. et al. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1. Thromb Haemost 1990; 63: 82-6.
• 3 Berrettini M. et al. Interaction of type 1 plasminogen activator inhibitor with the enzymes of the contact activation system. J Biol Chem 1989; 264: 11738-43.
• 4 Ehrlich HJ. et al. Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor-1 with thrombin inhibitory properties. J Biol Chem 1990; 265: 13029-35.
• 5 Keijer J. et al. On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site. Blood 1991; 78: 1254-61.
• 6 Urano T. et al. The inhibition of human factor Xa by plasminogen activator inhibitor type 1 in the presence of calcium ion, and its enhancement by heparin and vitronectin. Biochim Biophys Acta 1996; 1298: 199-208.
• 7 Urano T. et al. Human thrombin and calcium bound factor Xa significantly shorten tPA-induced fibrin clot lysis time via neutralization of plasminogen activator inhibitor type 1 activity. Thromb Haemost 1998; 80: 161-6.
• 8 Urano T. et al. Coagulation-associated enhancement of fibrinolytic activity via a neutralization of PAI-1 activity. Semin Thromb Hemost 2000; 26: 39-42.
• 9 Gaffney PJ. et al. The haemostatic balance -- Astrup revisited. Haemostasis 1999; 29: 58-71.
• 10 Hull RD. et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-82.
• 11 Fiessinger JN. et al. Once-daily subcutaneous dalteparin,a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost 1996; 76: 195-9.
• 12 Holmer E. et al. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin. Biochem J 1981; 193: 395-400.
• 13 Urano T. et al. A substrate-like form of plasminogen-activator-inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate. Eur J Biochem 1992; 209: 985-92.
• 14 Jameson GW. et al. Determination of the operational molarity of solutions of bovine alphachymotrypsin, trypsin, thrombin and factor Xa by spectrofluorimetric titration. Biochem J 1973; 131: 107-17.
• 15 Urano T. et al. Activated protein C attenuates coagulation-associated over-expression of fibrinolytic activity by suppressing the thrombin-dependent inactivation of PAI-1. J Thromb Haemost 2003; 01: 2615-20.
• 16 Urano T. et al. Soluble thrombomodulin quenches thrombin-mediated neutralization of PAI-1 activity and inhibits fibrinolysis through a TAFI independent mechanism. Fibrinolysis Proteolysis 1999; 13: 264-71.
• 17 Fears R. Kinetic studies on the effect of heparin and fibrin on plasminogen activators. Biochem J 1988; 249: 77-81.
• 18 Sakata Y. et al. Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor. Blood 1986; 68: 1218-23.
• 19 Wu K. et al. The cleavage and inactivation of plasminogen activator inhibitor type 1 by neutrophil elastase: the evaluation of its physiologic relevance in fibrinolysis. Blood 1995; 86: 1056-61.
• 20 Urano T. et al. The profibrinolytic enzyme subtilisin NAT purified from Bacillus subtilis cleaves and inactivates plasminogen activator inhibitor type 1. J Biol Chem 2001; 276: 24690-6.
• 21 Sui GC, Wiman B. Functional effects of single amino acid substitutions in the region of Phe113 to Asp138 in the plasminogen activator inhibitor 1 molecule. Biochem J 1998; 331: 409-15.
• 22 Ehrlich HJ. et al. Elucidation of structural requirements on plasminogen activator inhibitor-1 for binding to heparin. J Biol Chem 1992; 267: 11606-11.
• 23 Gebbink RK. et al. Specific glycosaminoglycans support the inhibition of thrombin by plasminogen activator inhibitor 1. Biochemistry 1993; 32: 1675-80.
• 24 Ehrlich HJ. et al. Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin. Biochemistry 1991; 30: 1021-8.
• 25 Rezaie AR. Role of exosites 1 and 2 in thrombin reaction with plasminogen activator inhibitor-1 in the absence and presence of cofactors. Biochemistry 1999; 38: 14592-9.
• 26 Huntington JA. Mechanisms of glycosaminoglycan activation of the serpins in hemostasis. J Thromb Haemost 2003; 01: 1535-49.
• 27 Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-92.
• 28 Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-74.
• 29 Siragusa S. et al. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996; 100: 269-77.
• 30 Lensing AW. et al. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 1995; 155: 601-7.
• 31 Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-98.
• 32 Warkentin TE. et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5.
• 33 Marini C. et al. Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial. Respiration 1988; 54: 162-73.
• 34 Stassen JM. et al. Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activator. Thromb Haemost 1987; 58: 947-50.
• 35 Vairel EG. et al. Heparin and a low molecular weight fraction enhances thrombolysis and by this pathway exercises a protective effect against thrombosis. Thromb Res 1983; 30: 219-24.
• 36 Lisman T, De Groot PG. Rebuttal to: Effect of heparin on TAFI-dependent inhibition of fibrinolysis. J Thromb Haemost 2003; 01: 200-1.
• 37 Chesebro JH. et al. Conjunctive antithrombotic therapy for thrombolysis in myocardial infarction. Am J Cardiol 1993; 72: 66G-74G.